Company news
Turn Therapeutics Inc. (NASDAQ:TTRX) news
Turn Therapeutics Inc. news releases on 6ix. Latest, Sep 10, 2026: Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Press releases & updates
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
September 10, 2026
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
September 9, 2026
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
August 20, 2026
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
August 12, 2026
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
July 28, 2026
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 7, 2026
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
July 6, 2026
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
June 1, 2026
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
May 27, 2026
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
May 18, 2026
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 30, 2026
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
March 23, 2026
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
February 17, 2026
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
February 9, 2026
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
January 7, 2026
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
November 11, 2025
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
November 11, 2025
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
November 4, 2025
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
October 30, 2025
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
October 22, 2025
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
October 20, 2025
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
October 15, 2025
Turn Therapeutics Appoints Arthur Golden to Board of Directors
October 14, 2025
Turn Therapeutics to Commence Trading Today on Nasdaq
October 8, 2025